This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pietrzyk, Z. Articles by Rabito, S. F. Search for Related Content PubMed PubMed Citation Articles by Pietrzyk, Z. Articles by Rabito, S. F. Related Collections Contractile function Animal models of human disease Myocardial cardiomyopathy disease Autonomic, reflex, and neurohumoral control of circulation Receptor pharmacology

(Hypertension. 2000;36:208.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Augmented Sympathetic Response to Bradykinin in the Diabetic Heart Before Autonomic Denervation

Zbigniew Pietrzyk; Stephen Vogel; Guenther J. Dietze; Sara F. Rabito

From the Department of Anesthesiology and Pain Management (Z.P., S.F.R.), Cook County Hospital, and the Department of Pharmacology (S.V.), University of Illinois College of Medicine, Chicago, and the Hypertension and Diabetes Research Unit (G.J.D.), Max Grundig Clinic, Buehl, Germany.

Abstract—We studied whether diabetes mellitus affects the bradykinin (BK)-induced release of norepinephrine (NE) from rat cardiac sympathetic endings in situ. Three groups were studied. Group A (n=12) was rendered diabetic with streptozotocin (STZ), group B (n=13) received STZ and insulin, and group C (n=14) received citrate buffer only. NPH insulin was given to group B from day 7 after STZ. Atria were paced (3Hz) with rectangular voltage pulses at mechanical threshold intensity (0.15 V/cm). The release of NE was assessed through its effects on contractile force in the presence of atropine (1 µmol/L). Intensifying the field stimulation above the neural threshold (0.4 V/cm) produced a graded positive inotropic effect that was due to the release of NE from sympathetic nerve endings. The additional effect of 0.1 µmol/L BK on the force of contraction was determined at half-maximal neural stimulation (ie, at 0.65 V/cm). Then, after washing out BK and lowering the stimulation intensity to mechanical threshold, a cumulative dose-response curve for added NE was generated, allowing the positive inotropic effects of neural stimulation (with or without BK) to be expressed in terms of an equivalent inotropic concentration of added NE ([NE_eq]). Neural stimulation, in the absence of BK, gave an [NE_eq] of 32±3 nmol/L in group A, 44±6 nmol/L in group B, and 37±6 nmol/L in group C. BK increased [NE_eq] by a factor of 6.2±0.9 in group A, 4.5±0.5 in group B, and 3.7±0.3 in group C. This factor was greater in group A than in group C but indistinguishable in groups B and C. Atria from normal and diabetic rats were incubated in ³[H]NE for 60 minutes. Excess tracer was removed, and atria were stimulated during a series of 1-minute episodes at half-maximal neural stimulation to cause exocytotic ³[H]NE release. BK augmented ³[H]NE release in normal (n=4) and in diabetic (n=4) atria. This BK-induced increase of ³[H]NE overflow (expressed as a fraction of tissue ³[H]NE radioactivity) was 4 times greater in diabetic than in normal preparations. The response to BK in releasing sympathetic neurotransmitter is augmented in diabetic rats, recovering in a manner dependent on insulin.

Key Words: bradykinin • diabetes mellitus • norepinephrine • insulin

This article has been cited by other articles:

				Z. Y. Fang, J. B. Prins, and T. H. Marwick Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications Endocr. Rev., August 1, 2004; 25(4): 543 - 567. [Abstract] [Full Text] [PDF]